Neurocrine nears buyout of Soleno Therapeutics in low‑$50s deal

Neurocrine Biosciences is reported to be in advanced talks to acquire Soleno Therapeutics, with the potential deal valuing Soleno in the low‑to‑mid $50s per share and implying a company valuation above $2.5 billion. Reports say discussions are progressing quickly, though no definitive agreement has been announced.

Sources indicate the negotiations could conclude swiftly if there are no last‑minute setbacks, a dynamic that pushed Soleno shares sharply higher in early trading while Neurocrine’s stock saw modest declines. Market commentary highlights that the implied price would represent a premium to Soleno’s recent trading levels.

The strategic rationale centers on Soleno’s commercialized treatment for hyperphagia associated with Prader‑Willi syndrome, VYKAT XR, which has reached initial commercial traction since launch; company disclosures and market reports note early sales and patient uptake that underpin buyer interest. That commercial performance is a key value driver in the reported talks.

For Neurocrine, the acquisition would add a revenue‑generating rare‑disease therapy to its existing portfolio and mark a significant inorganic expansion step for the midsized drugmaker. The move would mirror recent sector activity where mid‑sized biopharma firms have pursued targeted acquisitions to broaden therapeutic exposure.

Analysts caution that until a definitive merger agreement is filed, terms remain subject to change and will require board approvals and potential regulatory review. Market participants will watch for an official announcement, which would clarify the per‑share offer, transaction structure and timing; until then, volatility in both SLNO and NBIX is likely to persist as speculation continues.